Table 2.

Adverse events in the safety population (n = 137).

Adverse event	N (%) N = 32
Anemia	6 (4.4)
Diarrhea/vomiting	4 (2.9)
AST/ALT increase	4 (2.9)
Increase in C-reactive protein	3 (2.2)
Muscle stiffness/numbness	3 (2.2)
Stomach pain	3 (2.2)
Knee injury	2∗ (1.6)
Upper respiratory tract infection	2 (1.6)
Bloating	1 (0.7)
Fracture of the right upper limb	1 (0.7)
Leg swelling	1 (0.7)
Leucopenia	1 (0.7)
Sciatica	1 (0.7)

∗Including one serious adverse event. ALT: alanine transaminase; AST: aspartate transaminase;